Canadian Guidelines on HIV Pre-exposure Prophylaxis and Non-Occupational Post Exposure Prophylaxis:
Darrell H. S. Tan, Mark W. Hull, Deborah Yoong, Cécile Tremblay, Patrick O’Byrne, Réjean Thomas, Julie Kille, Jean-Guy Baril, Joseph Cox, Pierre Giguere, Marianne Harris, Christine Hughes, Paul MacPherson, Shannon O’Donnell, Joss Reimer, Ameeta Singh, Lisa Barrett, Isaac Bogoch, Jody Jollimore, Gilles Lambert, Bertrand Lebouche, Gila Metz, Tim Rogers and Stephen Shafran; for the Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network.
CMAJ November 27, 2017 189 (47) E1448-E1458; DOI: https://doi.org/10.1503/cmaj.170494
- Pre-exposure prophylaxis (PrEP) involving daily tenofovir disoproxil fumarate/emtricitabine 300/200 mg, taken orally, is a highly effective strategy for reducing the risk of HIV acquisition in adults who are at high, ongoing risk of infection.
- In gay, bisexual and other men who have sex with men with frequent exposures, an on-demand regimen may also be considered.
- Nonoccupational postexposure prophylaxis (nPEP) involving 28 days of antiretroviral medications is an effective strategy for reducing the risk of HIV acquisition from a recent (within 72 h) incident of moderate or high-risk exposure to HIV.
- PrEP and nPEP should be part of a combination prevention strategy that includes behavioural interventions, such as condoms and counselling on risk reduction.
URL for full guidelines
For more information on prescribing PrEP See CTN 303’s CME module:
To find out if PrEP is right for you see the patient module:
The Canadian HIV-HCV Co-infection Guidelines list 53 specific recommendations for:
- Evaluating co-infected patients
- Addressing barriers to care
- Selecting treatments
- Determining treatment timing
- Addressing drug-to-drug interactions.
The Canadian HIV Pregnancy Guidelines list 24 specific recommendations for:
- Antenatal care
- Intrapartum care
- Postpartum care
The goal of this workshop is to provide a multidisciplinary view of the current state of nonalcoholic steatohepatitis (NASH) in HIV and establish a collaborative platform for related research projects.
Dr. Card, CTN Postdoctoral Fellow, provides an overview of his fellowship project, using national survey data to shed light on patterns of substance use and how they relate to HIV risk in gbMSM.
Bridging the Gap: Community and researchers allied in fight to end HIV There is a line in Tony Kushner’s 1991…
The 22nd International AIDS Conference (AIDS 2018) is the premier gathering for individuals working in the field of HIV, policy makers,…